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Transcriptomic heterogeneity

Predicting treatment resistance

Infant acute lymphoblastic leukemia (ALL) is an especially aggressive form
of leukemia, particularly among patients with a rearrangement in the
KMT2A gene (KMT2A-r). Approximately two-thirds of infants with KMT2Ar ALL relapse within a year of initial diagnosis, with relapsed disease
particularly resistant to treatment and associated with high mortality. The
ability to better predict which patients are likely to relapse, especially
relative to current residual disease detection methods like flow cytometry,
would greatly improve treatment selection and patient outcome. In this
study, we set out to identify novel prognostic markers in patient data at
diagnosis using single-cell RNA sequencing (scRNAseq) data.

Uniform Manifold Approximation and Projection (UMAP) shows
transcriptional similarity between cells (individual points) across samples.

Cell assignment as “sensitive” or “resistant” to treatment – per Candelli
et al., 2022 – correlates with, but is not predictive of, prognosis. Patients
who relapse have cells with higher resistance scores and a higher
proportion of resistant cells compared to patients who do not relapse.
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Differential expression analysis
Dimensionality reduction & clustering using Seurat (v4.0.2) in R 4.0.3
Wilcoxon rank sum test (log fold change > 0.25, p < 0.05)
Patients who went on to relapse (n = 19) vs. no relapse (n = 6)
Treatment sensitivity/resistance prediction
As published in Candelli et al., 2022, each cell is assigned “resistance” and
“sensitivity” scores based on expression of prednisone-responsive genes,
identified in Rhein et al., 2007
Resistant cell: resistance score > median AND sensitivity score < median
Sensitive cell: sensitivity score > median AND resistance score < median

Prognostically significant markers
Differential expression analysis reveals 484
genes more highly expressed in patients
who went on to relapse and 461 genes more
highly expressed in patients who did not.

Patients who
do not relapse

Data acquisition
10x Chromium single-cell Multiome sequencing (v1 chemistry) – resulting
in scRNAseq counts matrix (genes x cells)
Blood or bone marrow from 25 KMT2A-r infant ALL patients at diagnosis
Data processed and aggregated using cellranger-arc (v2.0.0)
Average of 1191 cells/patient, with median 2223 genes/cell
Filtered down to cancer cells (89.14% of cells) for downstream analysis

Cells cluster based on patient identity (left), suggesting highly patientspecific transcriptomes, consistent with previous studies. Relapse status
does not predict patient similarity, as indicated by UMAP proximity (right).

Left: expression of differentially expressed
genes across patients.
Below: gene expression is heterogeneous
across and within individual patient cells.
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Conclusions
Infant ALL cancer cells have highly heterogeneous transcriptomes
Single-cell RNAseq enables identification of prognostically significant
marker genes, although these also show heterogeneous expression
Prediction of individual cell sensitivity or resistance to treatment
correlates with patient outcome, but is not strictly predictive
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